Three Generations of GLP-1 Research Peptides
The GLP-1 receptor agonist class has evolved rapidly, from single-agonist semaglutide to dual-agonist tirzepatide to triple-agonist retatrutide. This comparison examines the receptor profiles, research dosing, and clinical trial findings across all three compounds to help researchers understand the landscape of incretin-based metabolic research.
Receptor Binding Profiles
Semaglutide — Single Agonist
Semaglutide selectively targets the GLP-1 receptor, promoting satiety signaling, delayed gastric emptying, and insulin secretion. Its specificity provides clean research data on isolated GLP-1 pathway effects.
Tirzepatide — Dual Agonist
Tirzepatide targets both GLP-1 and GIP receptors. The GIP component adds enhanced energy expenditure modulation and lipid metabolism effects beyond what GLP-1 alone provides.
Retatrutide — Triple Agonist
Retatrutide targets GLP-1, GIP, and glucagon receptors. The glucagon component adds hepatic fat oxidation and thermogenesis, creating the most comprehensive metabolic activation profile of the three.
Clinical Trial Comparison
| Parameter | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Max studied dose | 2.4mg/week | 15mg/week | 12mg/week |
| Administration | Weekly SC injection | Weekly SC injection | Weekly SC injection |
| Clinical phase | FDA approved | FDA approved | Phase 2 completed |
Dosing Comparison
Each compound uses a titration approach to minimize GI side effects. See individual dosage guides: Semaglutide dosage chart, Tirzepatide dosage guide, and Retatrutide dosage guide.
Safety Profile Comparison
All three compounds share a similar GI side effect profile (nausea, diarrhea, vomiting) that is dose-dependent and generally improves with titration. Retatrutide’s glucagon component introduces additional considerations around hepatic effects that are being characterized in ongoing research.
Which to Choose for Research?
The choice depends on the research question: semaglutide for isolated GLP-1 studies, tirzepatide for dual-incretin research, and retatrutide for investigating the synergistic effects of triple receptor activation on metabolic parameters.
For research and educational purposes only. Browse our catalog and verify purity at COAs.